


 <b>Methodist Dallas Medical Center</b>	<b>Title:</b> Transplant Candidate Selection Criteria	<b>Effective Date:</b> 10/16/2015
	<b>Section:</b> Kidney and Pancreas	
<b>Approved by:</b>  Richard Dickerman, M.D., Surgical Director, Kidney/Pancreas Transplant		<b>Revision Date(s):</b> 03/04/2016;12/11/2018; 03/01/2020;02/09/2021; 07/2021;08/2021; 9/2022; 11/2025  <b>Next review Date:</b> 11/2028
 Jose Castillo-Lugo, M.D., Medical Director, Kidney/Pancreas Transplant		
 Melody Holder, Director of Transplant Clinical Operations		

**Purpose:** To ensure timely and uniform selection of candidates for kidney and pancreas transplant waitlist registration

**Indications for Kidney Transplantation**

- Creatinine clearance: 20 ml per minute by eGFR (no race modifier), 24 hour urine collection or Glofil OR
- Currently on regular maintenance dialysis with the start date validated from appropriate source document (such as CMS form 2728)
- Methodist Dallas Medical Center will not discriminate against a potential organ recipient solely on the basis of an individual’s disability

**Contraindications to Kidney Transplantation**

1) Absolute Contraindications

- Active infection
- Active malignancy or metastatic disease (see attached table; page 3)
- Active Multiple Myeloma
- Significant cardiovascular disease
- Significant liver disease
- Morbid obesity
- Psychiatric disorders unresponsive to treatment
- Non- adherence to medication and/or treatment regimen
- Ongoing substance dependency or abuse
- Inadequate financial/social resources to manage post-transplant regimen

2) Relative Contraindications

- Recipients with a BMI up to 35 may be accepted depending on body habitus, fat distribution and surgeon discretion. Recipients with a BMI of 35+ may be accepted with the recommendation of a transplant surgeon.
- Recipients who are current smokers and have a history of diabetes, any cardiac or vascular events (MI’s, PVD, carotid disease, amputations) or interventions (peripheral or cardiac angioplasties/stents, peripheral vascular bypass, etc) may be required to stop smoking prior to evaluation. The committee may require documented negative carboxyhemoglobin prior to beginning evaluation.

## **Selection Criteria for Simultaneous Pancreas/Kidney Transplant (SPK), Pancreas after Kidney Transplant (PAK), Pancreas Transplant Alone (PTA)**

### **Indications for SPK, PAK or PTA Transplantation**

- Diabetes with:
    - C-Peptide of < 2 ng/ml or:
    - C-Peptide of > 2 ng/ml and a BMI of 30 or less
- 1) Absolute contraindications for SPK, PAK or PTA:
- Same as for kidney only transplant.
  - BMI over 30
  - Age over 50 years of age for PTA
  - Evidence of significant cardiovascular disease
  - Current smoker
- 2) Relative Exclusions:
- 55 years of age or older for SPK/PAK transplants. Candidates age 55-60 may be considered in a case by case basis
  - 55 years of age or older for PTA
  - Inadequate cardiopulmonary function
  - Inability to follow strict post-transplant follow-up regimen
  - PAK: Creatinine clearance of  $\geq 40$ cc/min.
  - PTA: Creatinine clearance of  $\geq 60$ cc/min.

**TABLE 14.****Recommended waiting times between cancer remission and kidney transplantation<sup>91</sup>**

<b>Breast</b>	Early	At least 2 years
	Advanced	At least 5 years
<b>Colorectal</b>	Dukes A/B	At least 2 years
	Duke C	2-5 years
	Duke D	At least 5 years
<b>Bladder</b>	Invasive	At least 2 years
<b>Kidney</b>	Incidentaloma ( $< 3$ cm)	No waiting time
<b>Uterine</b>	Early	At least 2 years
	Large and invasive	At least 5 years
	Localized	At least 2 years
<b>Cervical</b>	Invasive	At least 5 years
	Localized	At least 2 years
<b>Lung</b>	Invasive	At least 5 years
	Localized	2-5 years
<b>Testicular</b>	Localized	At least 2 years
	Invasive	2-5 years
<b>Melanoma</b>	Localized	At least 5 years
	Invasive	Contraindicated
<b>Prostate</b>	Gleason $\leq 6$	No waiting time
	Gleason 7	At least 2 years
	Gleason 8-10	At least 5 years
<b>Thyroid</b>	Papillary/Follicular/ Medullary	
	Stage 1	No waiting time
	Stage 2	At least 2 years
	Stage 3	At least 5 years
	Stage 4	Contraindicated
	Anaplastic	Contraindicated
<b>Hodgkin Lymphoma</b>	Localized	At least 2 years
	Regional	3-5 years
	Distant	At least 5 years
<b>Non-Hodgkin Lymphoma</b>	Localized	At least 2 years
	Regional	3-5 years
	Distant	At least 5 years
<b>Post-transplant lymphoproliferative disease</b>	Nodal	At least 2 years
	Extranodal and cerebral	At least 5 years